Popular Trials
Alkylating agents
Stem Cell Transplant for Scleroderma
This trial tests a treatment for systemic scleroderma involving stem cell collection, high-dose chemotherapy, and immune suppression, followed by returning the patient's own stem cells and using a maintenance drug to prevent disease recurrence. The treatment has shown a satisfactory risk-benefit ratio in earlier studies.
Enzyme
Hyaluronidase + CO2 Laser for Small Mouth
This trial explores combining two treatments to improve mouth mobility, hygiene, self-esteem, and quality of life for people with scleroderma-induced microstomia. Laser-assisted drug delivery used to reduce pain of injections. 3 laser sessions at 4-8 week intervals, followed by 3mo follow-up.
Popular Filters
Trials for Multiple Sclerosis Patients
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
Trials for MS Patients
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
Phase 3 Trials
mTOR inhibitor
Long-Term Safety of Everolimus for Tuberous Sclerosis
This trial is for patients with TSC and refractory seizures who are currently receiving everolimus treatment and are determined to be benefiting from it, in order to evaluate the long-term safety of the treatment.
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
Trials With No Placebo
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Procedure
Extracorporeal Photopheresis for Systemic Sclerosis
This trial is testing a treatment called Extracorporeal Photopheresis for patients with a severe form of scleroderma. The treatment involves taking blood out, treating it with light and a drug, and then putting it back in. The goal is to see if this can safely reduce skin thickening and improve symptoms. Extracorporeal photopheresis (ECP) has been used for over 30 years, initially for cutaneous T-cell lymphoma and later for other diseases including scleroderma.
Phototherapy
UVA-1 Phototherapy for Scleroderma
This trial will use a single-blind, prospective, randomized (dominant/non-dominant hand) comparator design to assess the effect of high dose (80-120 J/cm2) UVA1 therapy on hand function in scleroderma in a paired t-test design. This study will be placebo-controlled (with a UV-blocking gloved hand), cross-over, randomized clinical trial.
View More Related Trials
Frequently Asked Questions
Introduction to morphea
What are the top hospitals conducting morphea research?
When it comes to clinical trials focused on morphea, a rare skin condition characterized by thickened and discolored patches of skin, several hospitals are leading the way. In London, the Rheumatology Clinic at St. Joseph's Health Care is actively conducting two trials dedicated to understanding and treating this condition. Although they have no recorded past trials for morphea, their commitment to current research demonstrates their dedication to finding solutions for patients.
Meanwhile, in Omaha, Nebraska, both the University of Nebraska Medical Center's Lauritzen Outpatient Center and Nebraska Medicine's Dermatology Westroads are contributing significantly as well. These institutions each have one active trial related to morphea and have also conducted one previous trial in the field since embarking on their respective journeys in 2023.
Additionally making strides in this area is Utah's University of Utah MidValley Dermatology where there is currently one ongoing clinical trial specifically targeting morphea alongside having accomplished another such study back when they initiated their first ever investigation into this particular field dated until 2020.
Lastly but not least Mayo Clinic situated amidst Arizona’s Scottsdale region continues being an integral part within fight against Morphea through its contemporary efforts with singleir ongoing clinical test while carrying out a precedent experiment nearly spanning over a year from2012 till present day
These leading hospitals serve as valuable centers for individuals affected by morphea who seek innovative treatments or hope to contribute to scientific advancements through participation in these essential trials. As we continue expanding our knowledge about this complex condition which affects so many lives globally; thus every small step taken towards understanding it better brings us closer creating new opportunities that offer support & renewed confidence those living with Morhpea
Which are the best cities for morphea clinical trials?
When it comes to morphea clinical trials, several cities are at the forefront of research. London, Ontario, Boston, Massachusetts, Houston, Texas, Omaha Nebraska and Scottsdale Arizona each have active trials focused on advancing our understanding and treatment options for this condition. These trials explore a variety of interventions such as Extracorporeal Photopheresis (ECP), Brentuximab Vedotin, Peripheral Blood Stem Cell Transplantation, Scleroderma treatments and more. By participating in these trials in these cities individuals with morphea can contribute to the development of new therapies that hold promise for improved outcomes.
Which are the top treatments for morphea being explored in clinical trials?
Clinical trials are shedding light on promising treatments for morphea, a condition characterized by hardened, discolored patches on the skin. Leading the charge is ixazomib, currently being explored in one active trial dedicated to morphea. This novel treatment option entered the scene in 2021 and shows great potential in addressing the symptoms of this rare skin disorder. Another contender making waves is sildenafil, which has caught researchers' attention with its inclusion in two all-time clinical trials for morphea since its first listing back in 2010. As these investigations progress, hope grows that new therapeutic breakthroughs will emerge to improve the lives of individuals affected by morphea worldwide.
What are the most recent clinical trials for morphea?
Exciting advancements are being made in the field of morphea, with several recent clinical trials offering hope for patients. One such trial focuses on anifrolumab, administered through subcutaneous weekly injections. In Phase 3, this treatment option became available on 7/13/2023 and holds promise for managing morphea symptoms effectively. Additionally, ongoing research is exploring the effectiveness of COVID-19 vaccines in addressing morphea, demonstrating potential benefits following Phases 2 and 3 that became available on 3/9/2022. Sildenafil has also shown promise in a Phase 2 trial conducted from 9/20/2021 onwards as a potential therapeutic option for those affected by morphea. These developments showcase the dedication to finding innovative solutions to improve quality of life for individuals battling this condition.
What morphea clinical trials were recently completed?
Recently, a clinical trial investigating the efficacy of Pirfenidone (PFD) in treating morphea reached completion. Led by Michael Roth, this study concluded in November 2017. While it is not within the timeframe of "recent" as per current information, this trial holds significance as an important contribution to our understanding and potential treatment options for morphea.